News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Microbix Biosystems Inc. (MBXBF)' Revenue Increases 35% in Third Quarter



8/14/2013 10:10:56 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TORONTO, Aug. 14, 2013 /CNW/ - Microbix Biosystems Inc. (TSX: MBX), a biotechnology company developing innovative biological products and technologies, today reported financial results for its third quarter ending June 30, 2013. Revenue was $1,906,652 compared to $1,413,531 for the same quarter last year, an increase of 35%. This increase is the result of continued growth in antigen sales in the quarter and ongoing consulting services provided to Zydus under the Kinlytic® license agreement. Operating expenses for the quarter were $1,026,841 compared to $1,437,660 for the same quarter last year, a reduction of $410,819.

Help employers find you! Check out all the jobs and post your resume.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES